Brian Furmanski, PhD

Brian Furmanski is the Chief Regulatory Officer at Kriya. Brian joined Kriya from Nuventra Pharma Sciences where he was the Senior Director of Clinical Pharmacology and Regulatory Affairs. Prior to Nuventra, Brian was a Senior Clinical Pharmacology Reviewer at the FDA where he reviewed and provided regulatory and scientific advice on hundreds of IND, NDA and BLA submissions. Before his time at the FDA, Brian was an investigator in the muscle metabolism and repair group at GlaxoSmithKline. He started his career at Siga Technologies where he contributed to the development of novel antiviral therapies. Brian received his PhD in biochemistry from the University of South Carolina and completed his postdoctoral fellowship at St. Jude Children’s Research Hospital. He received his undergraduate degrees in economics and engineering, also from the University of South Carolina.